Publications by authors named "Khyatiben Rana"
Article Synopsis
- Many patients using statins and ezetimibe still do not meet LDL-C lowering goals, leaving them at risk for cardiovascular disease despite following recommended guidelines.
- The introduction of PCSK-9 inhibitors was a positive step in cholesterol management, but their high cost and method of administration have hindered widespread use, highlighting the need for more accessible treatments.
- Bempedoic acid, a new investigational drug, shows promise in effectively lowering LDL-C and may serve as a valuable addition to existing therapies, especially since it avoids certain side effects of statins.
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
Am J Cardiovasc Drugs
October 2020
Article Synopsis
- Cardiovascular disease (CVD) is a major problem for patients with type 2 diabetes (T2DM), leading to high rates of illness and death.
- Many T2DM patients are receiving treatments to prevent CVD, but significant risks still persist, especially for atherosclerotic CVD (ASCVD).
- Recent studies indicate that certain antidiabetic drugs, particularly SGLT-2 inhibitors, show promise in reducing major adverse cardiovascular events (MACE) and may offer valuable prevention strategies for CVD in different groups of patients.
Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of <70 mg/dL or target non-high-density lipoprotein goal of <100 mg/dL.
View Article and Find Full Text PDFAim: HER2 testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib and neratinib. There is a paucity of reports describing the utilization rates of HER2 testing in large outpatient populations.
Methods: The Statewide Planning and Research Cooperative System (SPARCS) was used to examine HER2 testing across the state of New York (USA) during the 2012-2016 period.